Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor Vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma...
Overview
Authors
Affiliations
The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette-Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is being tested against medium-dose IFN-α2b in stages IIB-III cutaneous melanoma (CM) patients (pts) after surgery in an open, randomized, Phase II/III study. We present the results of the Phase II part of the ongoing CASVAC-0401 study (ClinicalTrials.gov: NCT01729663). Thirty-one pts were randomized to the CSF-470 vaccine ( = 20) or to the IFN-α2b arm ( = 11). During the 2-year treatment, immunized pts should receive 13 vaccinations. On day 1 of each visit, 1.6 × 10 irradiated CSF-470 cells plus 10 colony-forming units BCG plus 100 µg rhGM-CSF were administered intradermally, followed on days 2-4 by 100 µg rhGM-CSF. IFN-α2b pts should receive 10 million units (MU)/day/5 days a week for 4 weeks; then 5 MU thrice weekly for 23 months. Toxicity and quality of life (QOL) were evaluated at each visit. With a mean and a maximum follow-up of 39.4 and 83 months, respectively, a significant benefit in the distant metastasis-free survival (DMFS) for CSF-470 was observed ( = 0.022). Immune monitoring showed an increase in antitumoral cellular and humoral response in vaccinated pts. CSF-470 was well tolerated; 20/20 pts presented grades 1-2 dermic reactions at the vaccination site; 3/20 pts presented grade 3 allergic reactions. Other adverse events (AEs) were grade 1. Pts in the IFN-α2b arm presented grades 2-3 hematological (7/11), hepatic (2/11), and cardiac (1/11) toxicity; AEs in 9/11 pts forced treatment interruptions. QOL was significantly superior in the vaccine arm ( < 0.0001). Our results suggest that CSF-470 vaccine plus BCG plus GM-CSF can significantly prolong, with lower toxicity, the DMFS of high-risk CM pts with respect to medium-dose IFN-α2b. The continuation of a Phase III part of the CASVAC-0401 study is encouraged.
Carri I, Schwab E, Trivino J, von Euw E, Nielsen M, Mordoh J Front Immunol. 2025; 15():1496204.
PMID: 39840067 PMC: 11747570. DOI: 10.3389/fimmu.2024.1496204.
Cancer vaccines: platforms and current progress.
Lei W, Zhou K, Lei Y, Li Q, Zhu H Mol Biomed. 2025; 6(1):3.
PMID: 39789208 PMC: 11717780. DOI: 10.1186/s43556-024-00241-8.
Mordoh J, Schwab E, Bravo A, Aris M, Barrio M Front Immunol. 2024; 15:1354710.
PMID: 38726010 PMC: 11079628. DOI: 10.3389/fimmu.2024.1354710.
Bravo A, Aris M, Panouillot M, Porto M, Dieu-Nosjean M, Teillaud J Front Immunol. 2023; 14:1231734.
PMID: 37691949 PMC: 10485604. DOI: 10.3389/fimmu.2023.1231734.
Mordoh A, Trivino Pardo J, Carri I, Barrio M, Mordoh J, Aris M BMC Med Genomics. 2023; 16(1):1.
PMID: 36604730 PMC: 9814418. DOI: 10.1186/s12920-022-01426-2.